# Technology Appraisal Virtual Committee Meeting

# [Committee D]

**Minutes:** **Confirmed**

**Date and Time:** **Wednesday 4 November 2020**

## Present:

* Nabeel Alsindi Present for all notes
* James Avery Present for notes 9 to 22
* Matt Bradley Present for all notes
* Sofia Dias Present for all notes
* Professor Paula Ghaneh Present for all notes
* Rebecca Harmston Present for all notes
* Dr Andrew Hitchens Present for all notes
* Robert Hodgson Present for all notes
* Dr Bernard Khoo Present for all notes
* Dr Soo Fon Lim Present for all notes
* Dr Guy Makin Present for all notes
* Professor Gary McVeigh [C] Present for all notes
* Professor David Meads Present for all notes
* Giles Monnickendam Present for all notes
* Dr Malcolm Oswald Present for all notes
* Baljit Singh Present for all notes
* Dr Lindsay Smith [VC] Present for all notes
* John Watkins Present for all notes

## NICE Staff In attendance:

* Jasdeep Hayre, Associate Director, NICE, Present for notes 16 to 22
* Linda Landells, Associate Director, NICE, Present for notes 1 to 15
* Gavin Kenny, Project Manager, NICE, Present for notes 16 to 22
* Kate Moore, Project Manager, NICE, Present for notes 1 to 15
* Sally Doss, Technical Adviser, NICE, Present for notes 1 to 8
* Alex Filby, Technical Adviser, NICE, Present for notes 9 to 15
* Caron Jones, Technical Adviser, NICE, Present for notes 16 to 22
* Fatima Chunara, Technical Analyst, NICE, Present for notes 1 to 8
* Amy Crossley, Technical Analyst, NICE, Present for notes 16 to 22
* Anita Sanga, Technical Analyst, NICE, Present for notes 9 to 15
* Mandy Brereton, Committee Operations Assistant Project Manager, NICE, Present for notes 1 to 5
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for all notes, NICE, Present for notes 1 to 5, 9 to 12 & 16 to 19
* Gemma Smith, Committee Operations Coordinator, NICE, Present for all notes
* Mandy Tonkinson, Public Involvement Adviser, NICE. Present for notes 1 to 5 & 9 to 12
* Ismahan Abdullah, Technology Appraisals Administrator, NICE, Present for notes 16 to 22
* Celia Mayers, Technology Appraisals Administrator, NICE, Present for all notes
* Sophie McHugh, Committee Operations Administrator, NICE Present for notes 9 to 22

## ERG Representatives in attendance:

* James Mahon, Liverpool Reviews & Implementation Group, University of Liverpool, Present for notes 1 to 5
* Sarah Nevitt, Liverpool Reviews & Implementation Group, University of Liverpool, Evidence Review Group, Present for notes 1 to 5
* Hannah Penton, Kleijnen Reviews Ltd, Present for notes 8 to 11
* Robert Wolff, Kleijnen Reviews Ltd, Evidence Review Group, Present for notes 8 to 11
* Bram Ramaekers, Kleijnen Reviews Ltd, Present for notes 15 to 18

## Clinical and Patient experts in attendance:

* Professor Peter Clark, Cancer Drugs Fund Clinical Lead, Present for notes 1 to 8
* Dr Alastair Greystoke, Clinical expert, Consultant Medical Oncologist, Newcastle Freeman Hospital, Present for notes 1 to 5
* Debra Montague, Patient Expert, Nominated by ALK Positive UK, Present for notes 1 to 5
* Sanjay Popat, Clinical expert, Consultant Medical Oncologist, BTOG on behalf of BTOG/RCP/ACP/RCR/NCRI, Present for notes 1 to 5
* Kye Gbangbola, Patient Expert, Nominated by Sickle Cell Society, Present for notes 9 to 12
* Sharon Hodgson, Commissioning Expert, Present for notes 9 to 12
* June Okochi, Patient Expert, Nominated by Sickle Cell Society, Present for notes 9 to 12
* Dr Paul Telfer, Clinical expert, Senior Lecturer in Haematology, Queen Mary University of London, Present for notes 9 to 12

## Other Non-public attendees:

* Emilene Coventry, Senior Medical Editor, NICE, Present for notes 9 to 15
* Olivia Havercroft, Senior Medical Editor, NICE, Present for notes 1 to 8
* Tomas Keating, Technical Analyst, NICE, Present for all notes
* Emily Leckenby, Technical Analyst, Present for all notes
* Anna Murray-Cota, HTA Analyst, NICE, Present for all notes
* Natalie Spray, Technology Appraisals Project Manager, Present for notes 1 to 8
* Thomas Strong, HTA Adviser, NICE, Present for notes 1 to 15
* Maroulla Whiteley, Business Analyst, NICE, Present for all notes

## Appraisal of Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group [ERG] representatives and representatives from Takeda.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.  
   1. David Meads declared a non-financial professional & personal Interest as the University of Leeds has received funding from Takeda for research in an unrelated area.
      1. It was agreed that this declaration would not prevent David from participating in discussions on this topic.
   2. Sanjay Popat declared direct financial and indirect conflicts as he does consultancy work and has received Honoraria from various companies including Pfizer, Novartis, and Roche
      1. It was agreed that this declaration would not prevent Sanjay from participating in this section of the meeting.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy before opening for discussion.

### Part 2 – Closed session [company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Final Appraisal Determination [FAD] was discussed by the committee.
2. A vote was taken. The options were:  
   **Option 1:** Yes – Accepted for routine commissioning   
   **Option 2:** No – Further data needed before committee can make a decision  
   **The committee voted for Option 1.**
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.

## Appraisal of Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group [ERG] representatives and representatives from Novartis.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
   1. No conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy before opening for discussion.

### Part 2 – Closed session [company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Appraisal Consultation Document [ACD] was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD]in line with their decisions.

## Appraisal of Erenumab for preventing migraine [ID1188]

### Part 1 – Open session

1. The Chair welcomed the invited Evidence Review Group [ERG] representatives and representatives from Novartis.
2. The Chair asked all committee members, ERG representatives and NICE staff present to declare any relevant interests.
   1. No conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy before opening for discussions.

### Part 2 – Closed session [company representatives, ERG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Final Appraisal Determination [FAD] was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.